US senators consider immigration changes for workers skilled in science and technology.

Some journal editors may be turning to self-citations to boost their impact factors, a blogger at the The Scholarly Kitchen writes.

The gut microbiome may have a key role in the development of kwashiorkor, a form of severe malnutrition, researchers say.

A resolution in the US House of Representative seeks to officially recognize Feb. 12 as Darwin Day, in honor of the anniversary of Charles Darwin's birth.

In Nature this week: draft chickpea genome sequence and more.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that revenues in the fourth quarter improved 6 percent year over year as its Specialty Diagnostics segment saw 12 percent growth.

NEW YORK (GenomeWeb News) – BG Medicine has completed a public offering of 6 million shares of its common stock, raising net proceeds of around $12.8 million.

NEW YORK (GenomeWeb News) – Link Technologies today announced that it has signed on Zirench Technology to be its distributor in China.

NEW YORK (GenomeWeb News) – The National Institutes of Health plans to fund research that seeks to uncover the mechanisms involved in the progression and differentiation of stem cells so that new induced pluripotent stem cells can be developed that are closely related to embryonic stem cells at t

Isis Pharmaceuticals and partner Genzyme announced this week that the US Food and Drug Administration has approved their antisense drug Kynamro, known generically as mipomersen, for the treatment of homozygous familial hypercholesterolemia.

PhaseRx announced this week that it has signed an RNAi delivery technology-evaluation deal with ag-bio giant Monsanto, a key step forward in the startup's effort to license out its core technology in areas outside its focus on human therapeutics.

Researchers from the Massachusetts Institute of Technology last week reported on the development of a new microfluidic-based approach to delivering macromolecules, including functional siRNAs, into cells without the need for a vector.

Researchers from the Hebrew University of Jerusalem last month reported on the discovery that double-stranded RNAs could be used to fight the honey bee parasite Varroa destructor when fed to the host, opening the door to a new strategy for fighting one of apiculture's bi

Troubled RNAi drug developer Marina Biotech this week disclosed that it has defaulted in making repayments of outstanding secured indebtedness, putting further pressure on the company as it skirts bankruptcy.

Alnylam Pharmaceuticals this week announced the publication of data from its phase I trial of the siRNA-based liver cancer drug ALN-VSP.

Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-221 Patent Number: 8,361,722 Filed: Oct. 17, 2011 Inventor: Carlo Croce, Ohio State University

Mirna Therapeutics has appointed Clay Siegall as an outside director on its board.

Mirimus said its customers now have the option to use Charles River Laboratories for the production and shipment of RNAi-engineered custom mouse models.

This article has been updated to include comments from Palmetto Medical Director Elaine Jeter. Originally published Jan. 26.

MOUNTAIN VIEW, Calif. – InVitae, a company specializing in using targeted next-generation sequencing to diagnose rare genetic diseases, is preparing to launch this year a $1,500 test to assess 270 inherited conditions.

Originally published Jan. 29. MOUNTAIN VIEW, Calif. – The Coriell Institute for Medical Research in partnership with IBM has launched a for-profit company that will store consumers' whole-genome sequencing data.

The US Food and Drug Administration this week released a new guidance that provides recommendations on when and how pharmaceutical companies and other investigators should consider genomic information in early-phase studies of a drug’s pharmacokinetics, pharmacodynamics, efficacy

MolecularMD Gains Exclusive IP Rights to Develop LKB1 Genetic Tests for NSCLC MolecularMD has garnered the exclusive right to use the patents on LKB1 mutations to launch genetic tests for non-small cell lung cancer.

Foundation Medicine has appointed Steven Kafka chief business officer, a newly created position. He joins the company from Aileron Therapeutics, where he served as chief operating officer and chief financial officer.

The Mayo Foundation for Medical Education and Research has been awarded US Patent No. 8,362,227, "Detection of Clostridium difficile." Franklin Cockerill, Thomas Smith, Jon Rosenblatt, and Lynne Sloan are named as inventors.